Core Insights - Innovent Biologics is set to present nearly 10 accepted clinical data on its novel oncology molecules at the ESMO Asia Congress 2024, highlighting the updated Phase 1 results of its TOPO1i CLDN18.2 ADC (IBI343) for previously-treated pancreatic cancer [1][4] Group 1: Clinical Data Presentation - The presentation will include a mini oral session on the updated results from a Phase 1 study of IBI343 in patients with advanced pancreatic ductal adenocarcinoma (PDAC) [2] - Other studies to be presented include a Phase 2 study of mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in locally advanced MSS CRC and various Phase 2 studies on treatments for advanced colorectal cancer and hepatocellular carcinoma [2][3] Group 2: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases [5] - The company has launched 11 products and has 5 new drug applications under regulatory review, with 3 assets in Phase III or pivotal clinical trials and 17 molecules in early clinical stages [5] - Innovent collaborates with over 30 global healthcare companies, including Eli Lilly and Sanofi, to enhance its research and development capabilities [5]
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024